



Genomic Health, Inc.  
Investor Relations Department  
301 Penobscot Dr.  
Redwood City, CA 94063  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: GHDX

Last Trade:	29.59
Trade Time:	4:00 PM ET May 22, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	24.81 - 33.96
Volume	N/A


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

**Genomic Health, Inc.** (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- May 13, 2017**  
[Prospective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate Cancer Patients](#)
- May 12, 2017**  
[Oncotype DX® Genomic Prostate Score™ \(GPS\) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease](#)
- May 10, 2017**  
[Genomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference](#)
- May 9, 2017**  
[Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress](#)
- May 4, 2017**  
[Genomic Health Announces Favorable Draft Local Coverage Determination \(LCD\) on Medicare Coverage for Use of Oncotype DX® Genomic Prostate Score™ in Patients with Favorable Intermediate-risk Prostate Cancer](#)

### Financials & Filings [\[ View all \]](#)

- Mar 15, 2017**  
[Annual Report \(10-K\)](#)
- Apr 28, 2017**  
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2017**  
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016**  
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016**  
[Quarterly Report \(10-Q\)](#)

